Longeveron (LGVN) Q4 2025 Earnings Call Transcript

Thank you, Jenny, and thank you all for joining us today. The strength of the company's stem cell science and success in ...

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.
Mena FN

Inmed Provides Update On Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND And Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed" or the " Company "), a pharmaceutical company focused on developing a pipeline of ...
manilatimes

Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID

SPRING BRANCH, Texas, March 11, 2026 (GLOBE NEWSWIRE)-- Callan JMB Inc. (NASDAQ: CJMB), ("Callan JMB” or the "Company”), an integrative logistics company empowering the healthcare industry and ...
Yahoo Finance

GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials

TAIPEI, March 5, 2026 /PRNewswire/ -- Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator ...

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement ...